UK Markets closed

Fresenius SE & Co. KGaA (0OO9.IL)

IOB - IOB Delayed price. Currency in EUR
Add to watchlist
34.81+0.17 (+0.48%)
At close: 06:23PM GMT

Fresenius SE & Co. KGaA

Else-Kröner-Strasse 1
Bad Homburg vor der Höhe 61352
49 6172 608 2485

IndustryMedical Care Facilities
Full-time employees312,734

Key executives

NameTitlePayExercisedYear born
Mr. Stephan SturmCEO, Pres & Chairman of Management Board - Fresenius Management SE3.56MN/A1963
Ms. Rachel Clare EmpeyCFO & Member of Management Board - Fresenius Management SE2.85MN/A1976
Dr. Francesco De MeoMember of Management Board - Fresenius Management SE2.45MN/A1963
Dr. Ernst WastlerMember of Management Board - Fresenius Management SE1.58MN/A1958
Mr. Rice PowellMember of Management Board - Fresenius Management SE4.05MN/A1955
Dr. Sebastian BiedenkopfChief Legal & Compliance Officer, Insurance, HR, Labor Relations Director and Member of Mgmt. Board604kN/A1965
Mr. Michael SenMember of Management BoardN/AN/A1968
Mr. Markus GeorgiSr. VP of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2020, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


Fresenius SE & Co. KGaA, a health care group, provides products and services for dialysis, hospitals, and outpatient medical care Germany and internationally. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed. The Fresenius Medical Care segment offers products and services for patients with chronic kidney failure. This segment offers dialyzers, hemodialysis machines, and related disposable products, as well as dialysis-related services. The Fresenius Kabi segment specializes in the therapy and care of therapy and care ill patients. This segment offers IV drugs, including intravenously administered generic drugs for oncology, anesthetics, analgesics, anti-infectives, and critical care; parenteral and enteral nutrition products; infusion solutions and blood volume substitutes for infusion therapy; biosimilars, a biological medicine for autoimmune diseases and oncology; medical devices and disposal used to administer IV generic drugs, infusion therapies, and clinical nutrition products; and transfusion products for collection of blood components and corporeal therapies. The Fresenius Helios segment operated 89 hospitals, approximately 130 outpatient clinics, and 6 prevention centers in Germany; and 46 hospitals, 70 outpatient clinics, and approximately 300 risk prevention centers in Spain. The Fresenius Vamed segment manages projects and provides services for hospitals and other health care facilities. This segment offers project consulting and development, planning, and turnkey construction services, as well as maintenance, technical management, and operational management services. The company was formerly known as Fresenius SE and changed its name to Fresenius SE & Co. KGaA in January 2011. Fresenius SE & Co. KGaA was founded in 1912 and is headquartered in Bad Homburg vor der Höhe, Germany.

Corporate governance

Fresenius SE & Co. KGaA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.